

Appendix 4

Excluded references

Excluded - in Cochrane

- 6 Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. *Lancet* 1999; 354(9178):569-70.
- 22 Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for Mucous Membrane Pemphigoid and Epidermolysis Bullosa Acquisita (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
- 25 Majumdar S, Mockenhaupt M, Roujeau JC, Townshend A. Interventions for toxic epidermal necrolysis. Majumdar S, Mockenhaupt M, Roujeau J-C, Townshend A. Interventions for Toxic Epidermal Necrolysis (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
- 57 Coulam CB. Immunotherapy with intravenous immunoglobulin for treatment of recurrent pregnancy loss: American experience. *Am J Reprod Immunol* 1994; 32(4):286-9.
- 59 Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. *Am J Reprod Immunol* 1995; 34(6):333-7.
- 71 Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. *Am J Reprod Immunol* 1996; 35(4):363-9.
- 117 Molica S, Musto P, Chiurazzi F et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study. *Haematologica* 1996; 81(2):121-6.
- 160 Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, crossover study. *Brain* 1996; 119 (Pt 4):1067-77.
- 163 van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.[comment]. *Neurology* 1990; 40(2):209-12.
- 164 Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. *Journal of Neurology, Neurosurgery & Psychiatry* 1993; 56(1):36-9.
- 166 Choudhary PP, Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. *QJM* 1995; 88(7):493-502.
- 168 Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. *Ann Neurol* 2001; 50(2):195-201.

Excluded references

- 169 Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.[see comment]. *Neurology* 2001; 56(4):445-9.
- 172 Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. *J Neurol* 1996; 243(3):280-5.
- 194 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. *Ann Neurol* 1997; 41(6):789-96.
- 195 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. *Ann N Y Acad Sci* 1998; 841:720-6.
- 197 Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. *Artif Organs* 2001; 25(12):967-73.
- 198 Wolfe GI, Barohn RJ, Foster BM et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. *Muscle & Nerve* 2002; 26(4):549-52.
- 209 Parton M, Mitsumoto H, Leigh PN. Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Parton M, Mitsumoto H, Leigh PN. *Amino Acids for Amyotrophic Lateral Sclerosis / Motor Neuron Disease (Cochrane Review)*. In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
- 209 Parton M, Mitsumoto H, Leigh PN. Amino acids for amyotrophic lateral sclerosis / motor neuron disease. Parton M, Mitsumoto H, Leigh PN. *Amino Acids for Amyotrophic Lateral Sclerosis / Motor Neuron Disease (Cochrane Review)*. In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
- 216 Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.[see comment]. *Neurology* 1998; 50(2):398-402.
- 219 Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.[see comment]. *Lancet* 1997; 349(9052):589-93.
- 220 Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. *Mult Scler* 1997; 3(2):137-41.
- 233 Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. *Eur J Neurol* 2002; 9(6):557-63.

Excluded references

Excluded - other

- 2 Anonymous. Immunoglobulins in inflammation. Consensus-assisted protocol development and discussion forum of a study protocol on adjuvant treatment of mediastinitis with immunoglobulins (pentaglobulin) after cardiac surgery (ATMI). *Eur J Surg Suppl* 1999; (584):1-100.
- 3 Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. [Review] [34 refs]. *Lupus*. 7 Suppl 2:S55-62, 1998 .
- 3 Asherson RA. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. [Review] [34 refs]. *Lupus*. 7 Suppl 2:S55-62, 1998 .
- 11 de Gracia J, Vendrell M, Guarner L et al. [The use of human gamma globulin in the treatment of common variable immunodeficiency].[see comment]. [Spanish]. *Med Clin (Barc)* 1995; 104(6):201-6.
- 11 de Gracia J, Vendrell M, Guarner L et al. [The use of human gamma globulin in the treatment of common variable immunodeficiency].[see comment]. [Spanish]. *Med Clin (Barc)* 1995; 104(6):201-6.
- 14 Francioni C, Fioravanti A, Gelli R, Megale F, Marcolongo R. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus]. [Italian]. *Recenti Prog Med* 1993; 84(10):679-86.
- 16 Gan HC, Hyoon K, Fong KY. Clinical outcomes of patients with biopsy-proven lupus nephritis in NUH. *Singapore Med J* 2002; 43(12):614-6.
- 20 Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. [Review] [19 refs]. *Clinical & Experimental Dermatology* 2002; 27(1):3-7.
- 28 Marggraf G, Arnold A, Geiger A et al. Concept of and preliminary trial protocol for adjuvant treatment of mediastinitis with immunoglobulins after cardiac surgery (ATMI): response to comments and criticism.[comment]. *Eur J Surg Suppl* 1999; (584):79-84.
- 29 Marggraf G, Neugebauer EA. A multicentre randomised placebo-controlled double-blind study on adjuvant treatment of mediastinitis with immunoglobulins (Pentaglobin) after cardiac surgery (ATMI): outline and preliminary study protocol for discussion. The ATMI Study Group. *Eur J Surg Suppl* 1999; (584):26-32.
- 34 Oppermann J, Mobius D. Therapeutical and immunological effects of methylprednisolone pulse therapy in comparison with intravenous immunoglobulin. Treatment in patients with juvenile chronic arthritis. *Acta Univ Carol [Med] (Praha)* 1994; 40(1-4):117-21.
- 35 Pap T, Reinhold D, Kekow J. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. *Scand J Rheumatol* 1998; 27(2):157-9.

Excluded references

- 41 Rump JA, Jahreis A, Schlesier M, Stecher S, Peter HH. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIg) infusions in 10 patients with common variable immunodeficiency (CVID). *Clinical & Experimental Immunology* 1997; 110(2):167-73.
- 42 Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.[see comment]. *Journal of the European Academy of Dermatology & Venereology* 2003; 17(6):641-5.
- 44 Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. *Eur J Dermatol* 2003; 13(4):377-81.
- 53 Balasch J, Creus M, Fabregues F, Font J, Martorell J, Vanrell JA. Intravenous immunoglobulin preceding in vitro fertilization-embryo transfer for patients with repeated failure of embryo transfer. *Fertility & Sterility* 1996; 65(3):655-8.
- 58 Coulam CB, Goodman C. Increased pregnancy rates after IVF/ET with intravenous immunoglobulin treatment in women with elevated circulating C56+ cells. *Early Pregnancy [Electronic Resource]* 2000; 4(2):90-8.
- 60 Coulam CB, Krysa LW, Bustillo M. Intravenous immunoglobulin for in-vitro fertilization failure. *Hum Reprod* 1994; 9(12):2265-9.
- 66 Hansbrough JF, Miller LM, Field TO Jr, Gadd MA. High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis. *Pediatr Infect Dis J* 1988; 7(5 Suppl):S49-56.
- 67 Heilmann L, von Tempelhoff GF, Pollow K. Antiphospholipid syndrome in obstetrics. [Review] [67 refs]. *Clinical & Applied Thrombosis/Hemostasis* 2003; 9(2):143-50.
- 80 Sher G, Maassarani G, Zouves C et al. The use of combined heparin/aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid antibodies. *Am J Reprod Immunol* 1998; 39(4):223-5.
- 85 Vaquero E, Lazzarin N, De Carolis C, Valensise H, Moretti C, Ramanini C. Mild thyroid abnormalities and recurrent spontaneous abortion: diagnostic and therapeutical approach.[see comment]. *Am J Reprod Immunol* 2000; 43(4):204-8.
- 91 Bowden, R. A.; Fisher, L. D.; Rogers, K.; Cays, M., and Meyers, J. D. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant.[comment]. *Journal of Infectious Diseases*. 1991 Sep; 164(3):483-7.
- 94 Bussel, J. B.; Berkowitz, R. L.; Lynch, L.; Lesser, M. L.; Paidas, M. J.; Huang, C. L., and McFarland, J. G. (Department of Pediatrics, Cornell Medical College, New York, NY, USA). Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. *American Journal of Obstetrics & Gynecology*. 1996 May; 174(5):1414-23.

Excluded references

- 101 Gaddipati, S.; Berkowitz, R. L.; Lembed, A. A.; Lapinski, R.; McFarland, J. G., and Bussel, J. B. (Department of Obstetrics, Gynecology, and Reproductive Science, Mount Sinai Medical Center, New York, NY 10029, USA). Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. *American Journal of Obstetrics & Gynecology*. 2001 Oct; 185(4):976-80.
- 107 Kiehl, M.; Stoll, R., and Domschke, W. [Intravenous immunoglobulin substitution in patients with ARC and AIDS (WR 3-6)]. [German]. *Immunitat Und Infektion*. 1994 Apr; 22(2):53-5.
- 108 Kiprof, D. D.; Nachtigall, R. D.; Weaver, R. C.; Jacobson, A.; Main, E. K., and Garovoy, M. R. (Department of Medicine, California Pacific Medical Center, University of California, San Francisco 94115, USA). The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. *American Journal of Reproductive Immunology*. 1996 Oct; 36(4):228-34.
- 109 Krickeberg, H.; Mauff, G.; Mertens, T.; Plum, G., and Heitmann, K. Lymphocyte proliferation in AIDS-related complex/Walter-Reed 5 patients: response to herpes simplex virus and tuberculin antigen and mitogen during intravenous immunoglobulin treatment. The ARC-IVIG Study Group. *Vox Sanguinis*. 1990; 59 Suppl 1:38-43.
- 111 Machado, C. M.; Dulley, F. L.; Boas, L. S.; Castelli, J. B.; Macedo, M. C.; Silva, R. L.; Pallota, R.; Saboya, R. S., and Pannuti, C. S. (BMT Program, Fundacao Pro Sangue Hemocentro de Sao Paulo, Discipline of Hematology, Brazil). CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. *Bone Marrow Transplantation*. 2000 Aug; 26(4):413-7.
- 112 Mertens, T.; Ramon, A.; Kruppenbacher, J. P.; Heitmann, K.; Pika, U.; Leyssens, N., and Lievens, M. Virological examinations of patients with AIDS-related complex/Walter-Reed 5 enrolled in a double-blind placebo-controlled study with intravenous gammaglobulin administration. Prognostic value of anti-p24 determination. The ARC-IVIG Study Group. *Vox Sanguinis*. 1990; 59 Suppl 1:21-9.
- 118 Nathan, F. E.; Herman, J. H.; Keashen-Schnell, M.; McFarland, J. G.; Besa, E. C.; Hadley, C., and Catalano, P. M. (Department of Medicine, Medical College of Pennsylvania, Philadelphia). Anti-Bak(a) neonatal alloimmune thrombocytopenia: possible prevention by intravenous immunoglobulin. *Pediatric Hematology & Oncology*. 1994 May-1994 Jun 30; 11(3):325-9.
- 119 Peltier, M. K.; Filipovich, A. H.; Bechtel, M.; Dirksen, C. L., and Englund, J. A. (Pharmacy Department, University of Minnesota Hospital and Clinic, Minneapolis 55455). Randomized double-blinded comparison of three intravenous immunoglobulin products in bone marrow transplantation. *Seminars in Hematology*. 1992 Jul; 29(3 Suppl 2):112-5.
- 122 Radder, C. M.; Kanhai, H. H.; de Beaufort, A. J.; Klumper, F. J., and Brand, A. (Afd. Verloskunde, Leids Universitair Medisch Centrum, Leiden). [Evaluation of gradual conversion to a less invasive therapeutic strategy for pregnant women with alloimmune thrombocytopenia in the fetus for prevention of intracranial hemorrhage]. [Dutch]. *Nederlands Tijdschrift Voor Geneeskunde*. 2000 Oct 14; 144(42):2015-8.
- 126 Semple, J. W.; Kim, M.; Lazarus, A. H., and Freedman, J. (Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, Ontario, Canada. semplej@smh.toronto.ca). Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. *Blood*. 2002 Aug 1; 100(3):1055-9.

Excluded references

- 129 Vittecoq, D.; Chevret, S.; Morand-Joubert, L.; Heshmati, F.; Audat, F.; Bary, M.; Dusautoir, T.; Bismuth, A.; Viard, J. P.; Barre-Sinoussi, F., and et, a. I. (Service d'Infectiologie, Hopital Paul-Brousse, Villejuif, France). Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. *Proceedings of the National Academy of Sciences of the United States of America*. 1995 Feb 14; 92(4):1195-9.
- 141 Brennan DC, Garlock KA, Lippmann BA et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. *J Am Soc Nephrol* 1997; 8(1):118-25.
- 143 Dunn DL, Gillingham KJ, Kramer MA et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. *Transplantation* 1994; 57(6):876-84.
- 159 Hahn, A. F, Bolton CF, Zochodne D and Feasby TE. Intravenous immunoglobulin treatment (Ivig) in chronic inflammatory demyelinating polyneuropathy (CIDP): a double blind placebo controlled crossover study. *Neurology* 1995; 45(Suppl 4):A416.
- 173 Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressive treatment for multifocal motor neuropathy. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. *Immunosuppressive Treatment for Multifocal Motor Neuropathy (Cochrane Review)*. In: *The Cochrane Library*, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
- 180 Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. *Ann Neurol* 2000; 48(6):919-26.
- 187 Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. [Review] [35 refs]. *Clinical & Experimental Immunology*. 104 Suppl 1:55-60, 1996 May .
- 189 Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. *Arch Dis Child* 1995; 72(1):25-8.
- 191 Pautas E, Cherin P, Piette JC et al. Features of polymyositis and dermatomyositis in the elderly: a case-control study. *Clinical & Experimental Rheumatology* 2000; 18(2):241-4.
- 193 Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. *Am J Med Sci* 1988; 295(5):438-43.
- 196 Huang CS, Hsu HS, Kao KP, Huang MH, Huang BS. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. *Acta Neurol Scand* 2003; 108(2):136-8.
- 211 van den Berg LH, Franssen H, Van Doorn PA, Wokke JH. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. *Journal of Neurology, Neurosurgery & Psychiatry* 1997; 63(5):674-7.
- 221 Fazekas F, Strasser-Fuchs S, Hartung HP. [Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update]. [German]. *Nervenarzt* 1998; 69(4):361-5.

Excluded references

- 222 Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.[erratum appears in Neurology 2002 Aug13;59(3):480]. Neurology 2002; 58(2):169-78.
- 223 Hommes OR, Maas-Enriquez M. ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis. Multiple Sclerosis. 6 Suppl 2:S27-32, 2000 Oct .
- 227 Poehlau D. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group. Mult Scler 2000; 6 Suppl 2:S21-3.
- 228 Poehlau D, Amoiridis G, Postert T et al. Intravenous immunoglobulin (IVIG) in the treatment of multiple sclerosis (MS) - results of a double blind, randomized, placebo controlled pilot study. J Neurol 1996; 243:S53.
- 230 Poehlau D, Amoiridis G, Postert T et al. Results of double-blind, randomised, placebo-controlled pilot study on the treatment of multiple sclerosis with intravenous immunoglobulin. Eur J Neurol 1996; 3 (Suppl 4):58.
- 231 Rothwell PM, Stewart RRC, Cull RE. A crossover trial of intravenous immunoglobulin versus methylprednisolone in multiple sclerosis. J Neurol 1994; 241:S152.
- 234 Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50(5):1273-81.
- 235 Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M. A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. Mult Scler 1997; 3(2):145-8.
- 236 Sorensen PS, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M. Intravenous Immunoglobulin G (IVIG) Reduces the Number of Gadolinium Enhancing Lesions on MRI in a Double-Blind Cross-Over Trial in Multiple Sclerosis (MS). J Neurol 1997; 244:S144.
- 237 Sorensen SP, Wanscher B, Schreiber K, Blinkenberg M, Jensen CV, Ravnborg M. A double-blind cross-over trial of intravenous immunoglobulin in multiple sclerosis: preliminary results. Eur J Neurol 1996; 3 (Suppl 4):34-5.
- 240 Teksam M, Tali T, Kocer B, Isik S. Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000; 42(12):885-9.
- 242 Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.[comment]. Am J Med 1990; 89(5):561-8.
- 263 Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 23;61(6):736-40.

Excluded references

276

Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Cheung N, Smithwick EM, O'Malley J, Barandun S, Hilgartner MW. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. *Blood*. 1983 Aug;62(2):480-6.